Avanir AVP-923 shows safety and efficacy results
AVP-923 combines dextromethorphan hydrobromide and low dose quinidine sulfate, and is currently being investigated in a Phase II clinical trial in central neuropathic pain in patients with multiple
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).